Source comparison
PT-141 vs Bremelanotide — Why the Name Matters
PT-141 and bremelanotide are chemically identical. Same amino acid sequence, same molecular weight, same mechanism of action. The difference is regulatory status. Bremelanotide received FDA approval in 2019 as Vyleesi, a prescription treatment for hypoactive s
This comparison does not assign a generated winner or score.
- PT-141 and bremelanotide are chemically identical. Same amino acid sequence, same molecular weight, same mechanism of action. The difference is regulatory status. Bremelanotide received FDA approval in 2019 as Vyleesi, a prescription treatment for hypoactive sexual desire disorder in premenopausal women. PT-141 is the research designation for the same compound when sold outside the approved-drug pathway.
- This naming distinction creates a critical compliance issue: suppliers cannot market PT-141 as "bremelanotide for research" without implying it's the FDA-approved drug being diverted for non-medical purposes. The FDA has sent warning letters to companies using brand names for research peptides, arguing it misleads buyers into thinking they're purchasing pharmaceutical-grade products with regulatory oversight. Research suppliers use the PT-141 designation exclusively to avoid this implication.
- Legal for research purchase
- Yes, when labeled 'for research use only'
- No. Prescription-only drug
- Research compounds are exempt from new drug approval under Section 505(i) of FD&C Act
- Research-grade PT-141 is the only legally accessible version for non-clinical use
- Requires prescription
- No
- Yes. Schedule IV due to abuse potential classification error (later corrected to unscheduled)
- PT-141 is not a controlled substance; Vyleesi is prescription-only
- Prescription requirement applies only to branded pharmaceutical, not research peptide
- Subject to FDA batch testing
- Yes. Every lot tested for potency, sterility, endotoxin
- Research peptides undergo third-party purity verification but not FDA oversight
- Lack of FDA batch testing doesn't mean lack of quality. Reputable suppliers use HPLC and mass spec
- Price per 10mg vial
- $45–$85 from licensed suppliers
- $950+ per auto-injector (1.75mg)
- Research-grade pricing reflects synthesis cost; pharma pricing includes regulatory and distribution overhead
- Price differential is 10–15×. Research purchasing is cost-effective for lab use
- Purity standard
- ≥98% (HPLC-verified)
- ≥99.5% (USP monograph requirement)
- Research-grade peptides meet investigational purity thresholds; pharma-grade must meet stricter USP standards
- 98% purity is sufficient for most research protocols. The 1.5% gap rarely affects outcomes